Otilonium Bromide: Antimuscarinic Agent for Neuroscience and Smooth Muscle Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄) is a solid, highly pure (≥98%) antimuscarinic agent that inhibits muscarinic acetylcholine receptors (AChRs), leading to reliable antispasmodic effects in smooth muscle models (APExBIO). It is soluble at ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol, supporting a wide range of experimental protocols (APExBIO). Otilonium Bromide is employed in neuroscience to dissect cholinergic signaling and is essential in mechanistic studies of smooth muscle contractility. The compound is supplied for research purposes only, not for clinical or diagnostic use, and is best stored at -20°C for optimal stability (APExBIO). These properties make it a benchmark tool for receptor modulation and motility disorder models (Vijayan et al., 2021).

Biological Rationale

Otilonium Bromide is an antimuscarinic agent designed to inhibit the action of acetylcholine at muscarinic receptors in smooth muscle tissues. Acetylcholine is a key neurotransmitter in both the central and peripheral nervous systems, mediating muscle contraction and numerous autonomic functions (Vijayan et al., 2021). Inhibiting its action allows researchers to study the physiological role of cholinergic signaling pathways, especially in contexts such as gastrointestinal motility and neuronal receptor modulation.

Muscarinic receptor antagonists like Otilonium Bromide are critical in experimental models addressing smooth muscle spasms and gastrointestinal motility disorders. By providing selective inhibition, Otilonium Bromide facilitates the mapping of receptor subtypes and downstream signaling events. The specificity of Otilonium Bromide for muscarinic AChRs minimizes off-target effects, supporting reproducibility across translational neuroscience and pharmacology studies (APExBIO).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide exerts its effects by competitively binding to muscarinic acetylcholine receptors (mAChRs), preventing acetylcholine from activating these G protein-coupled receptors (Vijayan et al., 2021). This inhibition reduces smooth muscle contractility, resulting in measurable antispasmodic effects. The compound’s action is reversible and concentration-dependent, enabling titration for varying experimental requirements.

At the molecular level, Otilonium Bromide’s quaternary ammonium structure confers high affinity for muscarinic receptor subtypes M2 and M3, which dominate in gastrointestinal and smooth muscle tissues. This targeted action has made Otilonium Bromide a tool of choice in investigations of cholinergic modulation, distinguishing it from less selective antimuscarinic agents. The compound also offers minimal central nervous system penetration due to its physicochemical properties, focusing its effects on peripheral tissues.

Evidence & Benchmarks

• Otilonium Bromide achieves ≥98% purity as verified by HPLC and NMR under standard laboratory conditions (APExBIO).
• The compound is soluble at ≥28.18 mg/mL in DMSO (ambient temperature, neutral pH), ≥55.8 mg/mL in water (22°C), and ≥91 mg/mL in ethanol (22°C), supporting its use in high-concentration workflows (APExBIO).
• Muscarinic receptor antagonism by Otilonium Bromide has been validated in smooth muscle contractility assays using both in vitro and ex vivo models (Vijayan et al., 2021).
• Otilonium Bromide is preferred in gastrointestinal motility disorder models due to its peripheral selectivity and minimized CNS effects (internal link).
• Short-term solution use and storage at -20°C are recommended to maintain chemical stability and pharmacological efficacy (APExBIO).

Applications, Limits & Misconceptions

Otilonium Bromide is widely applied in neuroscience research, gastrointestinal motility disorder models, and smooth muscle spasm studies. As an antimuscarinic agent, it enables the parsing of receptor-mediated physiological responses and supports translational research targeting cholinergic pathways.

• Neuroscience receptor modulation: Otilonium Bromide provides a high degree of control in experiments dissecting muscarinic receptor function and signaling cascades (internal link—this article updates the mechanistic focus with new quantitative benchmarks).
• Smooth muscle spasm research: Its robust antispasmodic action makes it ideal for simulating and modulating motility disorders in animal and cell-based models (internal link—we clarify solution stability and workflow efficiency).
• Translational pharmacology: Otilonium Bromide’s characteristics facilitate cross-model comparison and preclinical validation.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not approved for diagnostic or therapeutic use in humans or animals; it is strictly for research applications (APExBIO).
• Its limited CNS penetration means it is unsuitable for studies requiring central nervous system antimuscarinic effects.
• Long-term storage in solution can result in degradation; only fresh solutions should be used for experiments.
• Use outside the recommended storage temperature (-20°C) may compromise integrity and efficacy.
• Results from Otilonium Bromide studies are not directly translatable to clinical outcomes without further validation.

Workflow Integration & Parameters

Otilonium Bromide integrates efficiently into established neuroscience and pharmacological workflows. Its high solubility allows preparation of concentrated stock solutions in DMSO, water, or ethanol, which can be diluted as needed. For typical in vitro receptor inhibition assays, concentrations ranging from 1 μM to 100 μM are employed, depending on the experimental model and target tissue. All dilutions should be made immediately before use, and solutions should not be stored for more than 24 hours at 4°C.

Storage of solid Otilonium Bromide at -20°C preserves its purity and activity. Aliquoting minimizes freeze-thaw cycles. Researchers can consult the Otilonium Bromide product page for further protocols and handling notes. For advanced applications and strategic integration, see this in-depth mechanistic review, which this article extends by providing solution stability and workflow guidance.

Conclusion & Outlook

Otilonium Bromide (APExBIO, SKU: B1607) is an established, high-purity antimuscarinic agent and acetylcholine receptor inhibitor for research, offering robust receptor selectivity, solubility, and reproducibility. Its use in neuroscience and smooth muscle research models advances mechanistic understanding of cholinergic signaling and motility disorders. With clear boundaries for application and handling, Otilonium Bromide remains an essential tool for modern receptor pharmacology and translational research, though results require contextual validation before clinical translation (Vijayan et al., 2021).